Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has Moderate or Severe loss of jawline definition as determined by the EI using the ALJDs (Grade 2 or 3 on the ALJDS) on both sides. The grade does not have to be the same on both sides, but must be Grade 2 or 3~* Treating Investigator (TI) considers the subject's jaw amenable to an improvement of at least 1 grade on the scale for the jawline definition~* Written Informed Consent (IC) has been obtained~Exclusion Criteria:~* Has ever received permanent facial implants (eg, polymethylmethacrylate, silicone, polytetrafluoroethylene) anywhere in the face or neck, or is planning to be implanted with any of these products during the study~* Has ever undergone fat injections in the malar, chin or jawline area or is planning to undergo this procedure during the study~* Has undergone semipermanent dermal filler treatment (eg, calcium hydroxyapatite, poly-L-lactic acid) below the subnasale within 36 months before enrollment or is planning to undergo such treatment during the study~* Has received deoxycholic acid treatment in the submental region in the last 6 months~* Has active autoimmune disease~* Females who are pregnant, nursing, or planning a pregnancy during the course of the study

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- VOLUX XC (Type: EXPERIMENTAL): Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with optional touch-up at day 30 and optional maintenance treatment at Month 12.
- No-treatment control (Type: EXPERIMENTAL): No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) at the beginning of the Post-Control period.

Based on this trial design, predict the completion outcome and termination type (if applicable).